Previous 10 | Next 10 |
LENSAR (LNSR): Q4 GAAP EPS of -$0.78 misses by $0.26.Revenue of $8.3M (-2.4% Y/Y) beats by $0.97M.Press Release For further details see: LENSAR EPS misses by $0.26, beats on revenue
Fourth Quarter 2020 Procedure Volumes Consistent with Fourth Quarter 2019 Levels Cash and Cash Equivalents of $40.6 Million as of December 31, 2020 LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technolog...
LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s fourth quarter and full year 2020 f...
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer, will present at tw...
We focus on value-oriented investing through rigorous fundamental analysis of a company's operations. Our portfolios generated strong returns over the past year on both an absolute and relative basis. The large cap strategy was up 53% net of fees in 2020. One of our larger contrib...
LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer will present at the 32nd Ann...
LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced that three posters and a paper have been accepted for virtual presenta...
LENSAR (LNSR): Q3 GAAP EPS of -$0.64.Revenue of $7.15M (-11.4% Y/Y)Press Release For further details see: LENSAR reports Q3 results
Procedure Numbers Consistent with 2019 Levels Cash and Cash Equivalents of $42.7 Million as of September 30, 2020 LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond l...
LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s third quarter 2020 financial results will be...
News, Short Squeeze, Breakout and More Instantly...
Total Revenue increased 28% and Procedure volume increased 25% over the first quarter of 2023 Increased ALLY ® Adaptive Cataract Treatment System installed base to 65 systems LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global m...